1
|
Echeverria GV, Ge Z, Seth S, Jeter-Jones SL, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, Ma X, Harris A, Wu Y, Moulder S, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Abstract GS5-05: Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs5-05] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Approximately 50% of patients with localized triple negative breast cancer (TNBC) have substantial residual cancer burden following treatment with neoadjuvant chemotherapy (NACT), resulting in distant metastasis and death for most of these patients. While genomic and phenotypic intra-tumor heterogeneity are pervasive features of TNBCs at the time of diagnosis, the functional contributions of heterogeneous tumor cell populations to chemoresistance have not been elucidated.
To investigate tumor evolution accompanying NACT, we employed orthotopic patient-derived xenograft (PDX) models of treatment-naïve TNBC, which retain intra-tumor heterogeneity characteristic of human TNBC. We discovered that some PDX models initially exhibited partial sensitivity to standard front-line NACT (Adriamycin plus Cytoxan, AC). Following AC, residual tumors were resistant to chemotherapy but repopulated tumors with chemo-sensitive cells if left untreated, indicating that tumor cells possessed inherent plasticity. To identify the tumor cell subpopulation(s) conferring chemoresistance, we conducted barcode-mediated clonal tracking in three independent PDX models by introducing a high-complexity pooled lentiviral barcode library into PDX tumor cells which were then orthotopically engrafted into recipient mice. Strikingly, residual tumors maintained the same heterogeneous clonal architecture as naïve tumors. Concordantly, whole-exome sequencing revealed conservation of genomic subclonal architecture throughout treatment. These results were corroborated by genomic sequencing of serial biopsies pre- and post-AC obtained directly from TNBC patients enrolled on an ongoing clinical trial at MD Anderson (ARTEMIS; NCT02276443). Together, these studies revealed that genomically distinct pre-treatment subclones were equally capable of surviving AC to reconstitute tumors after treatment.
To identify functional addictions of residual tumor cells, we conducted histologic and transcriptomic profiling. Residual tumors following AC-treatment exhibited extensive fibrotic desmoplasia and tumor cell pleomorphism in both PDX models and in serial biopsies obtained from TNBC patients enrolled on the ARTEMIS trial. Strikingly, these AC-induced features were reverted upon regrowth of residual tumors in PDXs and in patients' tumors. Similarly, residual tumors exhibited unique transcriptomic features, many of which are also de-regulated in cohorts of human TNBCs undergoing chemotherapy treatment. These features were nearly completely reverted after tumors regrew, suggesting that the residual tumor state may be a unique and transient therapeutic window. Gene set enrichment analyses revealed that residual tumors had increased activation of oxidative phosphorylation and decreased glycolytic signaling. Pharmacologic targeting of oxidative phosphorylation with a small-molecule inhibitor of mitochondrial electron transport chain complex I (IACS-010759) significantly delayed the regrowth of AC-treated residual tumors in three independent PDX models. Collectively, these studies reveal that a reversible phenotypic state can confer chemoresistance in the absence of genomic selection and that the residual tumor state is a novel therapeutic window for chemo-refractory TNBC.
Citation Format: Echeverria GV, Ge Z, Seth S, Jeter-Jones SL, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, Ma X, Harris A, Wu Y, Moulder S, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS5-05.
Collapse
Affiliation(s)
- GV Echeverria
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - Z Ge
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - S Seth
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - SL Jeter-Jones
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - X Zhang
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - X Zhou
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - S Cai
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - Y Tu
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - A McCoy
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - M Peoples
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - R Lau
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - J Shao
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - Y Sun
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - C Bristow
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - A Carugo
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - X Ma
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - A Harris
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - Y Wu
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - S Moulder
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - WF Symmans
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - JR Marszalek
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - TP Heffernan
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - JT Chang
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - H Piwnica-Worms
- The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| |
Collapse
|
2
|
Shariati M, Paez-Arango N, Bristow CA, Evans KW, Peoples MD, Carugo A, Heffernan TP, Meric-Bernstam F. Abstract P6-18-13: Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple-negative breast cancer (TNBC) is among the most aggressive subtypes, accounts for 10-15% of all breast cancer cases and is characterized by a lack of hormone receptors with a low overall survival rate. Due to the heterogeneity nature of this disease, the absence of validated molecular targets makes it unresponsive to conventional therapies. PI3K/Akt/mTOR pathway is aberrantly activated in TNBC, but single agent therapy is commonly subject to resistance. The goal of this study is to identify the genes that can be targeted to enhance the efficacy of mTOR inhibitor TAK228, an agent that is being investigated as a treatment for advanced solid tumors, in TNBC with PI3K pathway activation. We utilized an in vivo pooled barcoded shRNA library screening to determine the genes that have the potential to be used as TAK228 synthetic lethal partners. Using deep sequencing analysis of the shRNA profiles, we identified several genes whose loss of function conferred synthetic lethality in the presence of TAK228. We found that targeting the candidate genes (WEE1, BMX and MAPK15) with their inhibitors (AZD1775, Ibrutinib and Sunitinib) did not significantly affect the viability, however combination treatment of these agents with TAK228 induced a robust growth inhibition and demonstrated a significant synergy in MDA-MB-468 cell lines. Investigating the activation of relevant survival signaling pathways will further elucidate the mechanism of synthetic lethal interaction. These observations provide a promising rational strategy for the treatment of TNBC with PI3K pathway aberration.
Citation Format: Shariati M, Paez-Arango N, Bristow CA, Evans KW, Peoples MD, Carugo A, Heffernan TP, Meric-Bernstam F. Identification of optimal combination therapy partners for PI3K/Akt/mTOR pathway inhibitor in triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-13.
Collapse
Affiliation(s)
- M Shariati
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - N Paez-Arango
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - CA Bristow
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - KW Evans
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - MD Peoples
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - A Carugo
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | - TP Heffernan
- The Uniaversity of Texas MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
3
|
Echeverria GV, Seth S, Ge Z, Sun Y, DiFrancesco E, Lau R, Marszalek J, Moulder S, Symmans F, Heffernan TP, Chang JT, Piwnica-Worms H. Abstract P4-03-02: Characterizing and targeting chemoresistant subclones in patient-derived xenograft models of triple negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-03-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Fifty percent of all triple negative breast cancer (TNBC) patients harbor significant residual tumor burden following treatment with standard neoadjuvant chemotherapy (NACT), resulting in poor prognosis. Recent studies in TNBC have revealed extensive intra-tumoral heterogeneity at the time of diagnosis and throughout disease progression, but the relative contributions of these heterogeneous populations of tumor cells to chemoresistance are not well understood.
The primary tumor, dermal metastasis, and germline reference were obtained from a patient with untreated metastatic TNBC. Tumor cells were engrafted into the humanized mammary fat pads of NOD/SCID mice to establish PDX models of the primary (PIM001-P) and metastatic (PIM001-M) tumors. RNA sequencing and whole-exome sequencing (WES), performed on the patient's primary and metastatic tumors and the first- and third- passage PDX models revealed transcriptomic profiles and subclonal heterogeneity of the patient's tumors were recapitulated in the PDX models.
Treatment of mice engrafted with PIM001-P tumors with NACT (Adriamycin plus cyclophosphamide, AC) resulted in partial response, the magnitude of which was diminished in mice bearing PIM001-M tumors. Tumor subclones were tracked during chemotherapy treatment in mice engrafted with PIM001-P tumors using lentiviral non-targeting DNA barcodes. Residual tumors maintained the clonal architecture of untreated tumors, and deep WES revealed stable maintenance of somatic mutant allele frequencies throughout treatment. Therefore, selection of pre-existing resistant clones did not lead to AC resistance in this model. Interestingly, only 25% of residual tumor clones contributed to primary relapse once treatment was halted, suggesting only a subpopulation of tumor cells was able to reconstitute the tumor.
RNA sequencing and reverse phase protein array revealed that while vehicle-treated and regrown tumors were highly similar, residual tumors harbored a unique profile characterized by numerous significant alterations in RNA and protein levels. Together, these results suggest that residual tumors enter into a transient drug-resistant state that is reversible. Residual tumors were enriched for alterations in pathways such as metabolism, extracellular matrix remodeling, and cell-cell communication. Pharmacologic targeting of the residual tumor state with an inhibitor of mitochondrial oxidative phosphorylation led to significant inhibition of tumor regrowth following AC treatment. Additional vulnerabilities identified in residual tumors are being targeted therapeutically with the goal of eradicating residual tumor cells.
Citation Format: Echeverria GV, Seth S, Ge Z, Sun Y, DiFrancesco E, Lau R, Marszalek J, Moulder S, Symmans F, Heffernan TP, Chang JT, Piwnica-Worms H. Characterizing and targeting chemoresistant subclones in patient-derived xenograft models of triple negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-03-02.
Collapse
Affiliation(s)
- GV Echeverria
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - S Seth
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - Z Ge
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - Y Sun
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - E DiFrancesco
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - R Lau
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - J Marszalek
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - S Moulder
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - F Symmans
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - TP Heffernan
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - JT Chang
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| | - H Piwnica-Worms
- The University of Texas M.D. Anderson Cancer Center, Houston, TX; Institute for Applied Cancer Science, The University of Teas M.D. Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center, Houston, TX
| |
Collapse
|
4
|
Powell E, Shao J, Picon HM, Ge Z, Echeverria GV, Peoples M, Bristow C, Cai S, Tu Y, McCoy AM, Piwnica-Worms D, Draetta G, Edwards JR, Moulder SL, Symmans WF, Heffernan TP, Liang H, Piwnica-Worms H. Abstract GS6-06: Identifying metastatic drivers in patient-derived xenograft models of triple negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-gs6-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Metastases are responsible for the vast majority of deaths due to breast cancer. Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high rates of metastasis and poor prognosis. We are employing patient derived xenograft (PDX) models of TNBC to identify drivers of metastasis. Tumor samples are obtained from the breast tumors of patients with TNBC and engrafted immediately into the humanized mammary fat pads of immune compromised mice. Lentiviral transduction was employed to express bioluminescent and fluorescent markers in two independent PDX models of TNBC. Using these models, we demonstrated that human breast tumors are capable of completing all stages of the metastatic cascade in mice, and metastatic lesions are observed in organs normally found in patients with metastatic breast cancer including lung, liver, bone, brain, and lymph nodes. Dynamic and reversible epithelial to mesenchymal transition (EMT) was observed as tumors metastasized to lung and were re-passaged to recipient mouse mammary glands. Lung metastases were isolated using bioluminescence imaging and lung metastasis gene expression signatures were generated. Metastasis signatures from two independent PDX models were compared to identify genes that were commonly de-regulated in lung metastases relative to corresponding mammary tumors. Comprehensive gain-of-function screens were then conducted in vivo to identify functional drivers of TNBC metastasis. Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) was identified as a metastatic driver in this screen. CEACAM5 mRNA and protein levels were elevated in lung metastases relative to corresponding mammary gland tumors in mice. In addition, we demonstrated that CEACAM5 expression was upregulated in the lung metastases of breast cancer patients, and its expression inversely correlated with patient survival. Our data indicate that the metastatic function of CEACAM5 is to promote growth of breast tumors in the lung by inducing MET (mesenchymal to epithelial transition).
Citation Format: Powell E, Shao J, Picon HM, Ge Z, Echeverria GV, Peoples M, Bristow C, Cai S, Tu Y, McCoy AM, Piwnica-Worms D, Draetta G, Edwards JR, Moulder SL, Symmans WF, Heffernan TP, Liang H, Piwnica-Worms H. Identifying metastatic drivers in patient-derived xenograft models of triple negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS6-06.
Collapse
Affiliation(s)
- E Powell
- MD Anderson Cancer Center; Washington University in St. Louis
| | - J Shao
- MD Anderson Cancer Center; Washington University in St. Louis
| | - HM Picon
- MD Anderson Cancer Center; Washington University in St. Louis
| | - Z Ge
- MD Anderson Cancer Center; Washington University in St. Louis
| | - GV Echeverria
- MD Anderson Cancer Center; Washington University in St. Louis
| | - M Peoples
- MD Anderson Cancer Center; Washington University in St. Louis
| | - C Bristow
- MD Anderson Cancer Center; Washington University in St. Louis
| | - S Cai
- MD Anderson Cancer Center; Washington University in St. Louis
| | - Y Tu
- MD Anderson Cancer Center; Washington University in St. Louis
| | - AM McCoy
- MD Anderson Cancer Center; Washington University in St. Louis
| | - D Piwnica-Worms
- MD Anderson Cancer Center; Washington University in St. Louis
| | - G Draetta
- MD Anderson Cancer Center; Washington University in St. Louis
| | - JR Edwards
- MD Anderson Cancer Center; Washington University in St. Louis
| | - SL Moulder
- MD Anderson Cancer Center; Washington University in St. Louis
| | - WF Symmans
- MD Anderson Cancer Center; Washington University in St. Louis
| | - TP Heffernan
- MD Anderson Cancer Center; Washington University in St. Louis
| | - H Liang
- MD Anderson Cancer Center; Washington University in St. Louis
| | - H Piwnica-Worms
- MD Anderson Cancer Center; Washington University in St. Louis
| |
Collapse
|
5
|
Heffernan T. Does a state of alcohol hangover impair event based prospective memory? Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.1730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionThe alcohol hangover state (AHS) is characterized by range of symptoms (e.g., drowsiness, fatigue, gastro-intestinal problems, dry mouth, nausea, sweating) that remain after ones blood-alcohol level returns to zero following a recent bout of excessive drinking. Recent findings have revealed a range of cognitive deficits associated with an AHS, including memory deficits. It is less clear what impact the AHS has upon everyday remembering; of which prospective memory is an excellent example (PM: memory for future plans/actions; such as remembering to perform a task at a specific time).AimsThe present study explored whether the AHS impairs everyday PM.MethodsTwenty-one AHS participants were compared with 28 non-AHS controls using a between-groups design. All completed a prospective remembering video procedure (prvp), which measured event-based pm. the prvp required the participant first to memorise a series of specific action-locations combinations and then to recall these combinations whilst viewing a CD clip of a busy shopping high street. Drug use (alcohol, smoking, etc.) and mood (anxiety and depression) were also measured, as these have been shown to have a deleterious impact upon PM.ResultsThe AHS group recalled significantly fewer event-based PM combinations on the PRVP compared with the non-AHS control group (P < 0.05). There were no significant differences between the groups on age, smoking, alcohol use or mood.ConclusionThese results confirm that a state of alcohol hangover impedes everyday prospective memory. The wider implications will be discussed at conference.Disclosure of interestThe author has not supplied his/her declaration of competing interest.
Collapse
|
6
|
Powell E, Shao J, Tieu T, Peoples M, Bristow C, Manyam G, Cai S, Tu Y, Edwards JR, Heffernan TP, Piwnica-Worms D, Liang H, Piwnica-Worms H. Abstract P6-01-08: Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-01-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Metastases are responsible for the vast majority of deaths due to breast cancer. Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high rates of metastasis and poor response to chemotherapy. We are using patient derived xenograft (PDX) models of TNBC to identify drivers of TNBC metastasis. Using these models, we demonstrated that human breast tumors are capable of completing all stages of the metastatic cascade in mice, and metastatic lesions are observed in organs normally found in patients with metastatic breast cancer including lung, liver, bone, brain and lymph nodes. Lentiviral transduction was employed to express both bioluminescent and fluorescent proteins in three distinct PDX models of TNBC. In this way, metastatic lesions can be isolated using bioluminescent imaging and circulating tumor cells (CTCs) are isolated by flow cytometry. A lung metastasis gene expression signature was generated and comprehensive gain-of-function screens are being conducted in vivo to validate this signature and identify functional drivers of TNBC metastasis.
Citation Format: Powell E, Shao J, Tieu T, Peoples M, Bristow C, Manyam G, Cai S, Tu Y, Edwards JR, Heffernan TP, Piwnica-Worms D, Liang H, Piwnica-Worms H. Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-01-08.
Collapse
Affiliation(s)
- E Powell
- MD Anderson Cancer Center; Washington University in St. Louis
| | - J Shao
- MD Anderson Cancer Center; Washington University in St. Louis
| | - T Tieu
- MD Anderson Cancer Center; Washington University in St. Louis
| | - M Peoples
- MD Anderson Cancer Center; Washington University in St. Louis
| | - C Bristow
- MD Anderson Cancer Center; Washington University in St. Louis
| | - G Manyam
- MD Anderson Cancer Center; Washington University in St. Louis
| | - S Cai
- MD Anderson Cancer Center; Washington University in St. Louis
| | - Y Tu
- MD Anderson Cancer Center; Washington University in St. Louis
| | - JR Edwards
- MD Anderson Cancer Center; Washington University in St. Louis
| | - TP Heffernan
- MD Anderson Cancer Center; Washington University in St. Louis
| | - D Piwnica-Worms
- MD Anderson Cancer Center; Washington University in St. Louis
| | - H Liang
- MD Anderson Cancer Center; Washington University in St. Louis
| | - H Piwnica-Worms
- MD Anderson Cancer Center; Washington University in St. Louis
| |
Collapse
|
7
|
Echeverria GV, Seth S, Moulder S, Symmans W, Chang J, Cai S, Heffernan T, Piwnica-Worms H. Abstract P3-06-04: Investigating clonal dynamics in triple negative breast cancer chemoresistance. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-06-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Approximately 50% of triple-negative breast cancer (TNBC) patients have extensive residual disease following neoadjuvant chemotherapy (NAC). These patients have a four-fold increase in mortality risk and an increased risk of distant metastases within three years (1). Understanding the molecular basis of resistance to NAC is expected to provide opportunities to better treat patients in the primary setting. Extensive intratumoral subclonal heterogeneity has been well documented in primary, treatment-naïve TNBC (2). Subclonal populations harboring distinct molecular profiles may confound targeted therapy strategies, yet the functional impact of subclonal heterogeneity in TNBC resistance to therapy is unknown. We are implementing DNA barcoding to quantitatively track changes in subclonal architecture pre- and post-treatment in patient-derived xenograft (PDX) models of TNBC in order to design novel combination therapies. Such barcoding strategies have been used to monitor clonal dynamics in breast cancer PDXs with great sensitivity (3).
We have established an orthotopic PDX from a treatment-naïve TNBC patient (PIM1, procured from a patient later found to have chemoresistant disease). In order to model chemoresistance, we treated PIM1 with Adriamycin and cyclophosphamide (AC), standard of care NAC for TNBC patients, which resulted in partial response but left residual disease. To characterize subclonal dynamics in response to NAC, we transduced freshly isolated PIM1 cells with a lentiviral library expressing 25 million unique DNA barcodes (Cellecta) using conditions to ensure each transduced cell contained a single unique barcode. Transduced cells were selected with puromycin, then orthotopically implanted into immuno-compromised mice. High-throughput barcode sequencing revealed reproducible maintenance of greater than 60,000 unique barcodes in PDX tumors. Comparison of barcode distribution in tumors treated with vehicle or NAC will reveal whether NAC selects for a subpopulation of cells during the development of resistance. Future directions will include whole-exome and RNA sequencing to characterize genomic changes associated with alterations in barcode distribution in response to NAC treatment. Our ultimate goal is to identify novel combination therapies to eliminate subclones that contribute to chemoresistance in primary TNBC.
References
1. Cortazar P, et al. (Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet 384(9938):164-172.
2. Shah SP, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395-399.
3. Nguyen LV, et al. (2014) DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts. Nat Commun 5.
Citation Format: Echeverria GV, Seth S, Moulder S, Symmans W, Chang J, Cai S, Heffernan T, Piwnica-Worms H. Investigating clonal dynamics in triple negative breast cancer chemoresistance. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-06-04.
Collapse
Affiliation(s)
- GV Echeverria
- M.D. Anderson Cancer Center, Houston, TX; University of Texas Health Science Center, Houston, TX
| | - S Seth
- M.D. Anderson Cancer Center, Houston, TX; University of Texas Health Science Center, Houston, TX
| | - S Moulder
- M.D. Anderson Cancer Center, Houston, TX; University of Texas Health Science Center, Houston, TX
| | - W Symmans
- M.D. Anderson Cancer Center, Houston, TX; University of Texas Health Science Center, Houston, TX
| | - J Chang
- M.D. Anderson Cancer Center, Houston, TX; University of Texas Health Science Center, Houston, TX
| | - S Cai
- M.D. Anderson Cancer Center, Houston, TX; University of Texas Health Science Center, Houston, TX
| | - T Heffernan
- M.D. Anderson Cancer Center, Houston, TX; University of Texas Health Science Center, Houston, TX
| | - H Piwnica-Worms
- M.D. Anderson Cancer Center, Houston, TX; University of Texas Health Science Center, Houston, TX
| |
Collapse
|
8
|
Heffernan T, Battersby L, Bishop T, O'Neill T. The Everyday Cognitive Consequences of Regular Use of Anabolic Androgenic Steroids in a Sporting Context. Eur Psychiatry 2015. [DOI: 10.1016/s0924-9338(15)30816-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
9
|
Wang Q, Ezhilarasan R, Zheng S, Gumin J, Heffernan T, Draetta G, Lang F, Verhaak R, Sulman E. GE-39 * VALIDATION OF GLIOMA SPHERE-FORMING CELLS AS MODELS OF GLIOBLASTOMA AND IDENTIFICATION OF NOVEL DRIVERS OF TUMORIGENESIS THROUGH COMPREHENSIVE GENOMIC CHARACTERIZATION. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou256.38] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Wang Q, Ezhilarasan R, Zheng S, Gumin J, Heffernan T, Draetta G, Lang F, Verhaak R, Sulman E. GE-38 * IDENTIFYING THE TREATMENT-RESISTANT MESENCHYMAL SIGNATURE BY COMPARATIVE ANALYSES BETWEEN GLIOMA SPHERE-FORMING CELLS AND THEIR GLIOBLASTOMAS OF ORIGIN. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou256.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Sulman EP, Wang Q, Ezhilarasan R, Goodman LD, Gumen J, Sun P, Aldape K, Alfred Yung W, Heffernan T, Draetta GF, Lang FF. THE TREATMENT-RESISTANT MESENCHYMAL SIGNATURE IN GLIOBLASTOMA DERIVES FROM TUMOR CELLS INDEPENDENT OF STROMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou206.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Heffernan T, Ramzan S, O’Neill T. EPA-0010 – The “Double Whammy Effect” Of Combined Smoking And Drinking Upon Everyday Prospective Memory And Executive Function. Eur Psychiatry 2014. [DOI: 10.1016/s0924-9338(14)77532-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
13
|
Owen L, Heffernan T, Bervoets AC, de Klerk S, Vreman RA, Olivier B, Brookhuis KA, Roth T, Verster JC, Verster JC, van Doornen LJP, Kleinjan M, Garssen J, de Haan L, Penning R, Olivier B, Slot KA. S14 * THE HEALTH AND BEHAVIOURAL CONSEQUENCES OF ALCOHOL HANGOVER. Alcohol Alcohol 2013. [DOI: 10.1093/alcalc/agt085] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Wardwell-Ozgo J, Dogruluk T, Gifford A, Zhang Y, Heffernan TP, van Doorn R, Creighton CJ, Chin L, Scott KL. HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene 2013; 33:1017-26. [PMID: 23435427 PMCID: PMC3982326 DOI: 10.1038/onc.2013.30] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2012] [Revised: 12/05/2012] [Accepted: 12/27/2012] [Indexed: 12/30/2022]
Abstract
Metastatic melanoma is a highly lethal disease notorious for its aggressive clinical course and eventual resistance to existing therapies. Currently we possess a limited understanding of the genetic events driving melanoma progression, and much effort is focused on identifying pro-metastatic aberrations or perturbed signaling networks that constitute new therapeutic targets. In this study, we validate and assess the mechanism by which homeobox transcription factor A1 (HOXA1), a pro-invasion oncogene previously identified in a metastasis screen by our group, contributes to melanoma progression. Transcriptome and pathway profiling analyses of cells expressing HOXA1 reveals up-regulation of factors involved in diverse cytokine pathways that include the TGFβ signaling axis, which we further demonstrate to be required for HOXA1-mediated cell invasion in melanoma cells. Transcriptome profiling also shows HOXA1’s ability to potently down-regulate expression of microphthalmia-associated transcription factor (MITF) and other genes required for melanocyte differentiation, suggesting a mechanism by which HOXA1 expression de-differentiates cells into a pro-invasive cell state concomitant with TGFβ activation. Our analysis of publicly available datasets indicate that the HOXA1-induced gene signature successfully categorizes melanoma specimens based on their metastatic potential and, importantly, is capable of stratifying melanoma patient risk for metastasis based on expression in primary tumors. Together, these validation data and mechanistic insights suggest that patients whose primary tumors express HOXA1 are among a high-risk metastasis subgroup that should be considered for anti-TGFβ therapy in adjuvant settings. Moreover, further analysis of HOXA1 target genes in melanoma may reveal new pathways or targets amenable to therapeutic intervention.
Collapse
Affiliation(s)
- J Wardwell-Ozgo
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
| | - T Dogruluk
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
| | - A Gifford
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
| | - Y Zhang
- Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
| | - T P Heffernan
- Institute for Applied Cancer Science, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - R van Doorn
- Department of Dermatology; Leiden University Medical Center, Leiden, The Netherlands
| | - C J Creighton
- Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
| | - L Chin
- 1] Institute for Applied Cancer Science, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA [2] Department of Genomic Medicine, Houston, TX, USA
| | - K L Scott
- 1] Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA [2] Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
15
|
Heffernan T, O’neill T. P-39 - The impact of second-hand smoke upon everyday prospective memory. Eur Psychiatry 2012. [DOI: 10.1016/s0924-9338(12)74206-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
16
|
Heffernan T, Green DW, McManus IC, Muncer S. Comments on Network analysis and lay interpretation: Some issues of consensus and representation by S. J. Muncer & K. Gillen. British Journal of Social Psychology 2011. [DOI: 10.1111/j.2044-8309.1998.tb01169.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Scholey AB, Owen L, Gates J, Rodgers J, Buchanan T, Ling J, Heffernan T, Swan P, Stough C, Parrott AC. Hair MDMA samples are consistent with reported ecstasy use: findings from a study investigating effects of ecstasy on mood and memory. Neuropsychobiology 2011; 63:15-21. [PMID: 20962543 DOI: 10.1159/000321833] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/25/2008] [Accepted: 04/26/2010] [Indexed: 11/19/2022]
Abstract
AIMS Our group has conducted several Internet investigations into the biobehavioural effects of self-reported recreational use of MDMA (3,4-methylenedioxymethamphetamine or Ecstasy) and other psychosocial drugs. Here we report a new study examining the relationship between self-reported Ecstasy use and traces of MDMA found in hair samples. METHODS In a laboratory setting, 49 undergraduate volunteers performed an Internet-based assessment which included mood scales and the University of East London Drug Use Questionnaire, which asks for history and current drug use. They also provided a hair sample for determination of exposure to MDMA over the previous month. RESULTS Self-report of Ecstasy use and presence in hair samples were consistent (p < 0.00001). Both subjective and objective measures predicted lower self-reported ratings of happiness and higher self-reported stress. Self-reported Ecstasy use, but not presence in hair, was also associated with decreased tension. CONCLUSION Different psychoactive drugs can influence long-term mood and cognition in complex and dynamically interactive ways. Here we have shown a good correspondence between self-report and objective assessment of exposure to MDMA. These data suggest that the Internet has potentially high utility as a useful medium to complement traditional laboratory studies into the sequelae of recreational drug use.
Collapse
Affiliation(s)
- A B Scholey
- Brain Sciences Institute, Swinburne University, Melbourne, Victoria, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Heffernan T, Clark R, Bartholomew J, Ling J, Stephens R, Stephens S. Does binge drinking in teenagers affect their everyday prospective memory? Drug Alcohol Depend 2010; 109:73-8. [PMID: 20071106 DOI: 10.1016/j.drugalcdep.2009.12.013] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2009] [Revised: 11/20/2009] [Accepted: 12/01/2009] [Indexed: 01/30/2023]
Abstract
AIMS To examine whether teenage binge drinking has an adverse effect upon everyday prospective memory (PM). DESIGN The study utilised an existing-groups design, with alcohol group: binge drinkers vs non-binge drinkers as the independent factor, and scores on the two PM memory subscales of the Prospective and Retrospective Memory Questionnaire (PRMQ) and the score on the Prospective Remembering Video Procedure (PRVP) as the dependent factors. Age, anxiety and depression scores, last alcohol use (in hours) and how many years spent drinking, were measured and analysed between the groups. SETTING Each participant was tested in a laboratory setting. PARTICIPANTS An opportunity sample of 21 'binge drinkers' (those drinking above 6 units for females and 8 units for males on 2 or more occasions per week) and 29 non-bingers were compared. MEASUREMENTS Self-reported everyday PM lapses were measured using the PRMQ. The PRVP was used as an objective measure of PM. Alcohol and other drug use were assessed by the University of East London Recreational Drug Use Questionnaire. The Hospital Anxiety and Depression Scale gauged self-reported levels of anxiety and depression. FINDINGS After controlling for age, anxiety and depression scores, last alcohol use and how many years spent drinking, there were no significant between-group differences on either the self-reported long-term or short-term PM lapses. However, binge drinkers recalled significantly fewer location-action combinations on the PRVP than non-binge drinkers. CONCLUSIONS The results of the present study suggest that binge drinking in the teenage years leads to impairments in everyday PM.
Collapse
Affiliation(s)
- T Heffernan
- Division of Psychology, Northumbria University, Northumberland Street, Newcastle-upon-Tyne, NE1 8ST, UK.
| | | | | | | | | | | |
Collapse
|
19
|
Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB. Dancing hot on Ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users. Hum Psychopharmacol 2006; 21:285-98. [PMID: 16856221 DOI: 10.1002/hup.773] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Non-drug factors such as ambient temperature can heighten the adverse effects of MDMA (3,4-methylendioxymethamphetamine) in animals. We assessed whether dancing and feeling hot on Ecstasy would be associated with more psychobiological problems in recreational users. METHODS In an internet study, 206 unpaid participants (modal age 16-24) reported that they had used recreational Ecstasy/MDMA. They completed a drug use questionnaire, the Prospective Memory Questionnaire (PMQ), questions about dancing and feeling hot when on Ecstasy, and psychobiological problems afterwards. RESULTS Those who danced 'all the time' when on Ecstasy, reported significantly more PMQ memory problems than the less intensive dancers. Prolonged dancing was also associated with more complaints of depression, memory problems, concentration and organizational difficulties afterwards. Feeling hot when on Ecstasy was associated with poor concentration in the comedown period, and with mood fluctuation and impulsivity off-drug. PMQ long-term problems demonstrated a significant curvilinear relationship with thermal self-ratings; more memory problems were noted by those who felt very hot, and by those who did not feel hot when on Ecstasy. CONCLUSIONS Non-drug factors such as dancing and feeling hot are associated with the incidence of psychobiological problems reported by recreational Ecstasy/MDMA users.
Collapse
Affiliation(s)
- A C Parrott
- University of Wales Swansea, Swansea, Wales, UK.
| | | | | | | | | | | |
Collapse
|
20
|
Parrott AC, Rodgers J, Buchanan T, Scholey AB, Heffernan T, Ling J. The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003). Psychopharmacology (Berl) 2004; 171:231-3. [PMID: 14634710 DOI: 10.1007/s00213-003-1600-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2003] [Accepted: 07/02/2003] [Indexed: 10/26/2022]
Affiliation(s)
- A C Parrott
- School of Psychology, University of East London, E15 4LZ, London, UK. a.c.
| | | | | | | | | | | |
Collapse
|
21
|
Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 2002; 17:309-12. [PMID: 12404677 DOI: 10.1002/hup.415] [Citation(s) in RCA: 110] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
RATIONALE The recreational use of MDMA/Ecstasy (3,4-methylenedioxymethamphetamine) is associated with many psychobiological problems, but there is a paucity of data on how these relate to the level of past use. OBJECTIVES to assess the incidence of Ecstasy-attributed problems as reported by novice, moderate and heavy users. METHODS 763 unpaid volunteers took part in a WWW study of recreational drug use. This report is based on the 282 Ecstasy users from that sample, who comprised 109 novice users (1-9 occasions), 136 moderate users (10-99 occasions), and 36 heavy users (+100 occasions). Yes/no responses were automatically recorded to a series of questions covering psychobiological problems experienced when drug-free, which were attributed by the respondents to their Ecstasy use. RESULTS Depression, memory problems, anxiety, mood fluctuation, poor concentration, infections, tremors/twitches and weight loss, were all significantly associated with the extent of Ecstasy use. Thus memory problems attributed to Ecstasy were reported by 19% of novice users, 52% of heavy users and 73% of heavy users (chi-square 42.74, df=2, p<0.001); many of the other variables showed similar trends. CONCLUSIONS The incidence of problems attributed to Ecstasy use, is directly related to the number of occasions it has been used.
Collapse
Affiliation(s)
- A C Parrott
- Recreational Drugs Research Group, School of Psychology, University of East London, London E15 4LZ, UK.
| | | | | | | | | | | |
Collapse
|
22
|
Abstract
RVH offers significant advantages to the corresponding abdominal procedure, including: the possibility for regional anesthesia, particularly in patients with poor medical conditions; reduced surgical trauma because of the absence of an abdominal incision; applicability in obese patients; shorter surgical time when performed by an experienced surgeon; decreased need for blood transfusions; lower risk for complications; faster postoperative recovery period; shorter hospitalization. The primary drawback to the use of RVH for early stage cervical cancer has always been the lack of lymph node dissection. This has now been modified by the widespread use of laparoscopic lymphadenectomy. The increasing reliability of noninvasive radiologic techniques has provided and will continue to provide greater possibilities for preoperative staging to best determine the needs of the patient. The authors believe that an oncologic surgeon familiar with advanced laparoscopic techniques and RVH is able to take advantage of the benefits of both routes. Furthermore, a surgeon skilled in these techniques and RAH has the tools to ideally care for the specific needs, of each patient. The authors encourage individualization of surgical management, with special emphasis on the revision of the role of RVH in gynecologic oncology.
Collapse
Affiliation(s)
- R Angioli
- Department of Obstetrics and Gynecology, University of Miami School of Medicine, Florida 33136, USA
| | | | | | | |
Collapse
|
23
|
Maroun LE, Heffernan T, Hallam D. The Untoward Side Effects of Interferon Therapy Correlate Well with the Spectrum of Symptoms that Make up the Down Syndrome. ACTA ACUST UNITED AC 1998. [DOI: 10.3104/dsresearch.91] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
24
|
Lusskin R, Korein J, Thompson WA, Heffernan T. Computer management of clinical information: capture and retrieval of clinical orthopedic data by means of the variable-field-length format. Bull N Y Acad Med 1972; 48:1014-32. [PMID: 4506643 PMCID: PMC1806836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|